Linezolide Accord

Linezolid, the active ingredient in Linezolide Accord, is an oxazolidinone antibiotic presented as an oral dosage form for oral use. It treats infections caused by susceptible Gram‑positive bacteria, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), in adult patients.

GNH USA supplies Linezolide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance, reliable logistics and dedicated customer support.

Linezolid is used to treat infections caused by resistant Gram‑positive bacteria across several clinical settings.

Complicated skin and soft‑tissue infections (cSSTI): provides effective coverage against MRSA and other susceptible Gram‑positive organisms. Hospital‑acquired and community‑acquired pneumonia: offers activity against resistant Gram‑positive pathogens responsible for lower respiratory infections. Vancomycin‑resistant Enterococcus (VRE) infections: used when alternative agents are limited, targeting resistant enterococcal strains.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Metallic taste - Vomiting - Insomnia

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome - Lactic acidosis - Optic neuropathy - Severe allergic reactions (anaphylaxis)

When prescribing Linezolid, clinicians should consider several safety precautions to minimize risks.

Renal impairment: assess renal function and monitor for drug accumulation. Hepatic impairment: monitor liver enzymes during therapy. Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. Prolonged therapy (>14 days): monitor complete blood count for hematologic toxicity. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Store at room temperature: keep in original packaging, protect from moisture and light.

Linezolid interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome and hypertensive reactions. - Tyramine‑rich foods: may precipitate hypertensive episodes due to MAO inhibition. - Rifampin: markedly reduces linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Phenytoin: may lower linezolid levels; consider therapeutic drug monitoring. - NSAIDs: combined with thrombocytopenia may increase bleeding risk.